Abstract: A urine testing strip and a urine testing system are provided. The urine testing system includes the urine test strip and a detection device. The urine test strip includes a working electrode, a counter electrode, a reference electrode, a trigger circuit and a protection layer. The protection layer covers the working electrode, the counter electrode and the reference electrode, and portions of the working electrode, the counter electrode and the reference electrode are exposed through an opening of the protection layer. The detection device includes a test strip receiving module and a wireless transmission module. The test strip receiving module is used to receive the test strip and to provide electric power to the test strip for obtaining a detection result. The wireless transmission module is used to transmit the detection result to a mobile computer device.

Abstract: A reduced graphene oxide-based biosensor includes a nano-structure field-effect transistor including a channel region which includes a reduced graphene oxide having a linking moiety to be bonded to a receptor specific to an analyte, and which is represented by a formula of —(C?O)—X—COOH, wherein X represents a C1-C3 alkenylene group or a C1-C3 alkylene group.

Abstract: A reduced graphene oxide-based biosensor includes a nano-structure field-effect transistor including a channel region which includes a reduced graphene oxide having a linking moiety to be bonded to a receptor specific to an analyte, and which is represented by a formula of —(C?O)—X—COOH, wherein X represents a C1-C3 alkenylene group or a C1-C3 alkylene group.

Abstract: Disclosed herein are an anti-biofilm composition and a method to inhibit or prevent cell adhesion and/or biofilm formation by a microorganism, in which use of 1,2,3,4,6-penta-O-galloyl-D-glucopyranose (PGG) is involved therein.

Abstract: A chemically-modified graphene includes a graphene layer and a plurality of functional groups that are grafted to the graphene layer and each of which is represented by —CO—R—COOH, wherein R is an optionally substituted C1-C5 alkylene group or an optionally substituted C1-C5 alkenylene group. A method for producing a chemically-modified grapheme includes subjecting a cyclic anhydride and graphite to a Friedel-Crafts reaction in the presence of a Lewis acid.

Abstract: The present invention discloses a magnetic nanocomposite for inhibiting/treating cancer and a method for fabricating the same. The magnetic nanocomposite comprises a core formed of a plurality of magnetic nanoparticles made of ferric ferrous oxide (Fe3O4); a shell made of a carboxy-functionalized polyaniline; and an anti-tumor medicine bound to the external surface of the shell. The method of the present invention fast fabricates the magnetic nanocomposite in a simple way. The medicine of the present invention has a longer half life and a better thermal stability. The present invention disperses the water-insoluble medicine in water uniformly to decrease the biological rejection. Moreover, the magnetic nanocomposite of the present invention is guided to the nidus by an external magnetic field to increase the local concentration of the medicine and provide an effective chemotherapy. Therefore, the present invention has competitive advantage over the conventional BCNU.

Abstract: The present invention proposes a magnetic nanocomposite with multi-biofunctional groups, which comprises a core and a shell wrapping the core, wherein the core contains magnetic nanoparticles, and wherein the shell is made of a conductive polymer with multi-biofunctional groups where a medicine, an antibody or a fluorescent label can be attached.

Abstract: The present invention discloses a magnetic nanomedicine for inhibiting/treating human prostate cancer, which comprises a core containing a magnetic particle having a diameter of less than 10 nm; a shell made of a carboxylated polyaniline and encapsulating the core; and a medicine covalently linked to the shell and able to inhibit/treat prostate cancer. The magnetic nanomedicine of the present invention not only has superior thermal stability and but also has water solubility higher than that of the conventional anti-prostate cancer medicine. Further, the magnetic nanomedicine of the present invention can be magnetically conducted to the cancer area to increase the local concentration of medicine and enhance the therapeutic effect.

Abstract: This invention is directed to a polyamic acid represented by the following formula (I), and an electrode having an active layer made from the polyamic acid of formula (I).

Abstract: An electrode for an electrochemical device includes a conductor, and an active layer formed on the conductor and including a polybenzimidazole polymer that contains at least one of the functional group of the following formula:

Abstract: A method for preparing a carboxylic polybenzimidazole includes reacting a polybenzimidazole polymer with a cyclic acid anhydride to form the carboxylic polybenzimidazole.

Abstract: A carboxylic polybenzimidazole includes at least one of the following functional group of formula (I): wherein G is a group containing a carboxylic acid end group or a carboxylated end group.

Abstract: This invention is directed to a polyamic acid represented by the following formula (I), and an electrode having an active layer made from the polyamic acid of formula (I).

Abstract: The present invention discloses a magnetic nanodrug for treating thrombosis, which comprises a core formed of magnetic nanoparticles, a shell enveloping the core and made of carboxyl-functionalized polyaniline, and a thrombosis-treatment drug covalently bonded to the shell. The magnetic nanodrug of the present invention is non-toxic to vascular endothelial cells, has superior stability, features superparamagnetism, and can be uniformly dissolved in water. Therefore, the magnetic nanodrug for treating thrombosis can be guided by an external magnetic field to concentrate on a specified region and increase the effect of thrombosis treatment.

Abstract: A chemically-modified graphene includes a graphene layer and a plurality of functional groups that are grafted to the graphene layer and each of which is represented by —CO—R—COOH, wherein R is an optionally substituted C1-C5 alkylene group or an optionally substituted C1-C5 alkenylene group. A method for producing a chemically-modified grapheme includes subjecting a cyclic anhydride and graphite to a Friedel-Crafts reaction in the presence of a Lewis acid.

Abstract: The present invention discloses a magnetic nanomedicine for inhibiting/treating human prostate cancer, which comprises a core containing a magnetic particle having a diameter of less than 10 nm; a shell made of a carboxylated polyaniline and encapsulating the core; and a medicine covalently linked to the shell and able to inhibit/treat prostate cancer. The magnetic nanomedicine of the present invention not only has superior thermal stability and but also has water solubility higher than that of the conventional anti-prostate cancer medicine. Further, the magnetic nanomedicine of the present invention can be magnetically conducted to the cancer area to increase the local concentration of medicine and enhance the therapeutic effect.

Abstract: A magnetic nanomedicine for tumor suppression and therapy, comprising: a core, made of magnetic nanoparticles; a shell, encapsulating said core and is made of carboxylated polyaniline (SPAnH); and a tumor suppression medicine Epirubicin (EPI) or Doxorubicin (DOX) covalently bonded onto said shell. Said magnetic nanomedicine is capable of improving its thermal stability, and it can be dissolved uniformly in water, plus its superparamagnetic property, thus it can be guided by an outside magnetic field to concentrate to the site of tumor distribution to increase the local medicine concentration and enhance therapy effect.

Abstract: Disclosed herein are an anti-biofilm composition and a method to inhibit or prevent cell adhesion and/or biofilm formation by a microorganism, in which use of 1,2,3,4,6-penta-O-galloyl-D-glucopyranose (PGG) is involved therein.

Abstract: A magnetic nanomedicine for tumor suppression and therapy, comprising: a core, made of magnetic nanoparticles; a shell, encapsulating said core and is made of carboxylated polyaniline (SPAnH); and a tumor suppression medicine Epirubicin (EPI) or Doxorubicin (DOX) covalently bonded onto said shell. Said magnetic nanomedicine is capable of improving its thermal stability, and it can be dissolved uniformly in water, plus its superparamagnetic property, thus it can be guided by an outside magnetic field to concentrate to the site of tumor distribution to increase the local medicine concentration and enhance therapy effect.

Abstract: The present invention provides a water-soluble self-acid-doped polyaniline blends, comprising a 70-90% weight percentage polyaniline derivative and 10-30% weight percentage at least a water-soluble polymer. The blend can be used to produce a conductive polymer film and/or a conductive-polymer composite film. In the present invention, a water-soluble self-acid-doped polyaniline derivative is blended with a water-soluble polymer to enhance the mechanical properties and the coating-to-substrate adhesion of the electric conductive polymer film or the electric conductive-polymer composite film, and increase the conductivity of the blender. In addition, the blend containing a water-soluble self-acid-doped polyaniline of the present invention is biotoxicity-free and has free radical-capture capability. Thus it can be used as a biocompatible and conductive biomedical material.